Pharmacokinetic and pharmacodynamic considerations in antibiotic selection for different pneumonia settings

Infectious Diseases in Clinical Practice

Volumn 6, Issue SUPPL. 2, 1997, Pages

  Ebert, Steven C ^a,b  

^a MERITER HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFEPIME; CEFRADINE; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORANIC ACID DERIVATIVE; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; IMIPENEM; LEVOFLOXACIN; LOMEFLOXACIN; LORACARBEF; MACROLIDE; MINOCYCLINE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; SULFAMETHOXAZOLE; TOBRAMYCIN; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

BIOAVAILABILITY; BRONCHUS MUCOSA; BRONCHUS SECRETION; DRUG BLOOD LEVEL; DRUG EFFICACY; EPITHELIUM; HAEMOPHILUS INFLUENZAE; HUMAN; LUNG ALVEOLUS MACROPHAGE; LUNG PARENCHYMA; MINIMUM INHIBITORY CONCENTRATION; PLEURA FLUID; PNEUMONIA; SHORT SURVEY; SPUTUM; STREPTOCOCCUS PNEUMONIAE; TARGET ORGAN;

EID: 0030665467     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199711002-00004     Document Type: Short Survey

References (28)

1. Lee L-J, Sha X, Gottfried MH, Howard JR, Dix RK, Fish DN. Penetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomy Pharmacotherapy. In press 1998.
2. Adam D, Heilmann H-D, Weismeier K. Concentrations of ticarcillin and clavulanic acid in human bone after prophylactic administration of 5.2 g of timentin. Antimicrob Agents Chemother 1987;31:935-9.
3. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance Antimicrob Agents Chemother 1992; 36:1176-80.
4. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother 1992;36:1171-5.
5. Valcke Y, Pauwels R, Van Der Straeten M. Pharmacokinetics of antibiotics in the lungs. Eur RespirJ 1990;3:715-22.
6. Honeybourne D. Antibiotic penetration into lung tissues. Thorax 1994;49:104-6.
7. Honeybourne D, Baldwin DR. The site concentrations of antimicrobial agents in the lung. J Antimicrob Chemother 1992;30:249-60.
8. Cunha BA. The antibiotic treatment of community-acquired, atypical, and nosocomial pneumonias. Med Clin North Am 1995;79:581-97.
9. Hitt JA, Gerding DN. Sputum antimicrobial levels and clinical outcome in bronchitis. Semin Respir Infect 1991; 6:122-8.
10. Hughes CE, Van Scoy RE Antibiotic therapy of pleural empyemas. Semin Respir Infect 1991;6:94-102.
11. Bergogne-Berezin E. Penetration of antibiotics into the respiratory tree. J Antimicrob Chemother 1981;8:171-4.
12. Waistad RA, Vilsvik JS, Thurmann-Nielsen E, Rolstad T The pharmacokinetics and distribution of ofloxacin into the lower respiratory tract. Drugs 1995;49(2 Suppl):S344-S345.
13. Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeybourne D. Azithromycin concentrations at the site of pulmonary infection. Eur Respir J 1990;3:886-90.
14. Gottfried MH, Rodvold KA, Danziger LH, Servi RJ. Intrapulmonary concentrations of clarithromycin and azithromycin at steady-state in normal healthy adults. In: Proceedings and abstracts of the 3rd International Conference on Macrolides, Azalides, and Streptogramins; January 24-27, 1996: Lisbon (Portugal): 1996.
15. Couraud L, Fourtillan JB, Saux MC, Bryskiker A, Vincent du Laurier M. Diffusion of ofloxacin into human lung tissue. Drugs 1987;34(1 Suppl):S37-S38.
16. Nagai H, Yamasaki T, Masuda M, et al. Penetration of levofloxacin into bronchoalveolar lavage fluid. Drugs 1993;45(3 Suppl).S259.
17. Barza M. Challenges to antibiotic activity in tissue. Clin Infect Dis 1994;19:910-5.
18. Hunt BE, Weber A, Berger A, Ramsey B, Smith AL. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob Agents Chemother 1995;39: 34-9.
19. Bryant RE, Hammond D. Interaction of purulent material with antibiotics used to treat Pseudomonas infections. Antimicrob Agents Chemother 1974;6:702-7.
20. Bodem CR, Lampton LM, Miller DP, et al. Endobronchial pH: relevance to aminoglycoside activity in gram-negative bacillary pneumonia. Am Rev Respir Dis 1983;127: 39-41.
21. Nilius AM. Flamm RK, Hensey DM, Beyer JM, Tanaka SK. The effect of medium pH on the susceptibility test results for H. influenzae to clarithromycin by three methods. In: Proceedings and abstracts of the 3rd International Conference on Macrolides, Azalides, and Streptogramins; January 24-27, 1996; Lisbon (Portugal): 1996.
22. Stockley RA, Dragisevic P, Burnett D, Hill SL. Role of β-lactamases in the response of pulmonary infections to amoxicillin/clavulanate. J Antimicrob Chemother 1989; 42(Suppl B):S73-S81.
23. Roosendaal R, Bakker-Woudenberg IAJM, van den Berghe-van Raffe JC, Michel MF. Continuous vs. intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother 1986;30:403-8.
24. Leggett JE, Fantin B, Ebert S, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonias and thigh-infection models. J Infect Dis 1989;159:281-92.
25. Vallee E, Azoulay-Dupuis E, Pocidalo J-J, Bergogne-Berezin E. Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infection. Antimicrob Agents Chemother 1992;36:1412-7.
26. Ebert SC, Craig WA. Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol 1990;11: 319-26.
27. Valcke Y, Vogelaers DP, Colardyn FA, Pauwels RA. Penetration of netilmicin in the lower respiratory tract after once-daily dosing. Chest 1992;101:1028-32.
28. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-81.